Homeopathic drug industry stakeholders suggest stronger label disclaimers with more details about health claims and regulatory oversight to defuse the Federal Trade Commission’s push for clinical trials to substantiate claims for their OTC products.
FTC is looking at homeopathic advertising largely due to market’s shift from primarily Rx products prescribed for individual users to mass-market formulations sold nationwide. However, discussions at a Sept